NLRP3
BGE-102: oral CNS-penetrant NLRP3 inhibitor
Lead indications: cardiometabolic disease, diabetic macular edema
NLRP3 is a critical component of the inflammasome. Chronic inflammasome activation results in inflammation that drives cardiometabolic, retinal, and neuroinflammatory diseases.
BGE-102 is a potential best-in-class NLRP3 inhibitor. In Phase 1, BGE-102 was well tolerated, with ≥90% suppression of IL-1β for 24 hours and median hsCRP reductions of 86%.
We anticipate QUELL CV Phase 2 results in the second half of 2026 and QUELL DME Phase 2 results in the second half of 2027.
Program
Mechanism of Action
Target dosing
Indication
Status
BGE-102
NLRP3 inhibitor
(CNS penetrant)
(CNS penetrant)
Oral QD
Chronic inflammation
Diabetic macular edema
Ph 2
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Ph 2
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program
BGE-102
BGE-102
Mechanism of Action
NLRP3 inhibitor
(CNS penetrant)
(CNS penetrant)
Target dosing
Oral QD
Indication
Chronic inflammation
Status
![]()
Ph 2
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Mechanism of Action
NLRP3 inhibitor
(CNS penetrant)
(CNS penetrant)
Target dosing
Oral QD
Indication
Diabetic macular edema
Status
![]()
Ph 2
Discovery
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
We have discovered structurally and mechanistically novel inhibitors that bind in a distinct region of NLRP3
